Tzu-Fei Wang: Drug–Drug Interactions Between DOACs and Prostate Cancer Therapies
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Cancer, adding:
“Concerned about drug – drug interactions between DOACs and prostate cancer therapies?
New study of 2,297 patients from Ontario and Alberta:
No increase in thrombosis with DOACs and enzalutamide or apalutamide
No increase in bleeding with DOAC and abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont , Cynthia Wu , Pietro Ravani , Dominick Bossé , Robert Talarico, Marc Carrier , Manish M. Sood
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 26, 2026, 14:45Sarah Giorgia Grazia Giannone: An Exciting Chapter in Gene Therapy Research
-
Jul 26, 2026, 14:21Javed Anees: Cerebral Collateral Circulation in Acute Ischemic Stroke
-
Jul 26, 2026, 14:11André Picard։ Canadian Blood Supplies Drop Sharply, Urgent Donor Appeal Issued
-
Jul 26, 2026, 13:54Lorenzo Scalia: New Review Highlights Anticoagulant Strategies for Elderly Patients With Atrial Fibrillation
-
Jul 26, 2026, 13:32Ahmed Kotb: A Practical Guide to Von Willebrand Disease
-
Jul 26, 2026, 12:42Emmanuel J Favaloro: Celebrating Excellence in Scientific Peer Review
-
Jul 26, 2026, 12:20Advancing Sickle Cell Care Through Advocacy – American Society of Hematology
-
Jul 26, 2026, 12:04Paolo Zamboni: Marking 50 Years in Medicine
-
Jul 26, 2026, 11:55William Wallace: Muscle Aging Emerges as the Strongest Mortality Predictor